Pam3CSK4, TLR1 and TLR2 Ligand [NBP2-25297] - 293 cells were transfected with pCMV/TLR1-2 plasmid and pNF-kB/SEAP plasmid using Lipofectamin 2000. After 48 hrs of transfection, 50 ng/ml of Pam3CSK4 was added. Cells were ...read more
Pam3CSK4, TLR1 and TLR2 Ligand [NBP2-25297] - Evaluation of the ligand activity on TLR2/NF-kB SEAPorter HEK 293 cell line. IML-102 cell line is a stably co-transfected cell line that expresses full-length human ...read more
Hu, Mu, ChSpecies Glossary
Func, In vitro, In vivo, LA
Please see the protocols for proper use of this product. If no protocol is available, contact technical services for assistance.
Pam3CSK4, TLR1 and TLR2 Ligand is a synthetic tripalmitoylated lipohexapeptide analog of the immunologically active N-terminal portion of bacterial lipoprotein. It activates monocytes and macrophages and is also a potent activator of proinflammatory transcription factor NF-kB. Pam3CSK4, TLR1 and TLR2 Ligand is recognized by a heterodimer formed between TLR1 and TLR2.Pam3CSK4, TLR1 and TLR2 Ligand stimulation: If your cell line does not naturally express TLR1+ TLR2, co-transfect with plasmids pCMV/TLR1and pCMV/TLR2. Forty-eight hrs after transfection, stimulate cells with 10 to 100 ng/ml of Pam3CSK4 for 6-24 hrs. Determine Pam3CSK4 stimulation using appropriate detection assays.
Pam3CSK4, TLR1 and TLR2 Ligand
Read Publications using NBP2-25297 in the following applications:
Be the first to review our Pam3CSK4, TLR1 and TLR2 Ligand and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.